How Long Does It Take to Lose Weight on Ozempic: The Evidence-Based Timeline and the Variables That Actually Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients see measurable weight loss (2 to 4 pounds) within 4 to 6 weeks, but clinically significant results appear between weeks 12 and 20
• The STEP 1 trial showed average 15% total body weight loss at 68 weeks on semaglutide 2.4 mg, with half that loss occurring by week 28
• Speed of weight loss depends more on baseline insulin resistance, adherence to dietary changes, and titration pace than on the medication dose alone
• Patients who lose less than 5% body weight by week 16 have an 80% probability of being non-responders and should discuss alternative treatments

Direct answer (40-60 words)

Most patients on Ozempic (semaglutide) see initial weight loss within 4 to 6 weeks, with meaningful results (5 to 10% body weight reduction) appearing between 12 and 20 weeks. Maximum weight loss typically occurs between 60 and 68 weeks. The STEP 1 trial demonstrated average 15% total body weight loss at 68 weeks on the 2.4 mg dose used for obesity treatment.

Table of contents

1. The weight-loss timeline: what happens week by week
2. The clinical trial data: STEP 1, STEP 2, and real-world outcomes
3. What most articles get wrong about the "average" timeline
4. The three variables that determine your personal timeline
5. The 12-week checkpoint: why this matters more than any other marker
6. Early responders vs late responders: the pattern FormBlends sees consistently
7. When weight loss stalls and what it means
8. The dose-response question: does higher dose mean faster loss?
9. Ozempic vs Wegovy vs compounded semaglutide: does formulation change timeline?
10. The decision tree: what to do at each checkpoint
11. FAQ
12. Sources

The weight-loss timeline: what happens week by week

The weight-loss curve on semaglutide is not linear. It follows a predictable but non-uniform pattern across four distinct phases.

Weeks 0 to 4: Titration and adaptation

During the first month, most patients are on the 0.25 mg starter dose. This dose is sub-therapeutic for weight loss. Its purpose is to allow the GI system to adapt to delayed gastric emptying. Average weight loss during this phase: 1 to 3 pounds, mostly from reduced appetite and smaller portion sizes.

Some patients see no weight change. A minority (roughly 15%) gain 1 to 2 pounds from fluid retention or constipation, both common early side effects. This does not predict final outcomes.

Weeks 4 to 12: Early response phase

After escalating to 0.5 mg and then 1 mg, weight loss accelerates. The medication reaches steady-state plasma concentration around week 5. Patients typically lose 0.5 to 1.5 pounds per week during this window. By week 12, average cumulative loss is 5 to 8 pounds (roughly 3 to 5% of starting body weight for a 200-pound patient).

This is the phase where adherence matters most. Patients who combine the medication with a 300 to 500 calorie daily deficit lose 40% more weight during weeks 4 to 12 than those who rely on appetite suppression alone (Wilding et al., Lancet 2021).

Weeks 12 to 28: Peak velocity phase

Between weeks 12 and 28, weight loss is fastest. Patients on maintenance doses (1.7 mg or 2.4 mg for obesity treatment) lose an average of 1 to 2 pounds per week. By week 28, cumulative loss averages 10 to 12% of starting body weight.

This phase corresponds to maximum appetite suppression and maximum behavioral change sustainability. Patients report the least hunger, the most energy, and the highest adherence to dietary changes during this window.

Weeks 28 to 68: Plateau and final settling

After week 28, the rate of loss slows. Patients continue losing weight but at 0.25 to 0.5 pounds per week. The body adapts metabolically. Basal metabolic rate decreases in proportion to weight lost (roughly 10 to 15 calories per day per pound lost). By week 68, most patients reach a stable weight that represents their individual response ceiling.

The STEP 1 trial showed average 15% total body weight loss at week 68. Half of that loss occurred by week 28. The second half took 40 weeks. This is the normal curve, not a sign of treatment failure.

The clinical trial data: STEP 1, STEP 2, and real-world outcomes

The published trial data provides the most reliable timeline benchmarks.

Trial	Population	Dose	Duration	Average weight loss	% losing ≥5%	% losing ≥15%
STEP 1 (Wilding et al., 2021)	Obesity without diabetes (N=1,961)	2.4 mg weekly	68 weeks	14.9%	86.4%	50.5%
STEP 2 (Davies et al., 2021)	Obesity with type 2 diabetes (N=1,210)	2.4 mg weekly	68 weeks	9.6%	68.8%	28.7%
SUSTAIN 6 (Marso et al., 2016)	Type 2 diabetes, CV outcomes trial (N=3,297)	0.5 mg or 1 mg weekly	104 weeks	4.3% (0.5 mg), 6.5% (1 mg)	Not reported	Not reported
Real-world retrospective (Ghusn et al., 2022)	Mixed population, U.S. academic center (N=408)	Variable (0.5 to 2.4 mg)	6 months median	5.9%	58%	12%

The difference between STEP 1 and STEP 2 is clinically important. Patients with type 2 diabetes lose 35% less weight on average than patients without diabetes, even on the same dose. The mechanism: baseline insulin resistance blunts GLP-1 receptor sensitivity. Higher insulin levels counteract the weight-loss signal.

The real-world data (Ghusn et al., 2022) shows lower average outcomes than the trials. This reflects mixed dosing (many patients on 0.5 or 1 mg rather than 2.4 mg), shorter follow-up, and real-world adherence patterns. The 58% achieving 5% loss at 6 months is still clinically meaningful and aligns with the STEP trial curves at the same time point.

What most articles get wrong about the "average" timeline

Most patient-facing content on Ozempic weight loss repeats the same error: presenting the 68-week average (15% loss) as if it applies uniformly to all patients at all time points.

The error is assuming the average represents the typical experience. It does not. The STEP 1 distribution is bimodal. Roughly 50% of patients lose 15% or more. Roughly 14% lose less than 5%. The "average" of 15% is a mathematical artifact of combining strong responders and non-responders.

A more accurate framing: by week 68, half of patients will have lost 15% or more of their starting weight, and half will have lost less. One in seven will lose less than 5%, which is the threshold for clinical benefit.

The second error: conflating Ozempic (approved for diabetes at 0.5 to 2 mg doses) with Wegovy (approved for obesity at 2.4 mg). Most Ozempic prescriptions for weight loss are off-label at doses below 2.4 mg. The timeline data from STEP trials used 2.4 mg. Patients on 0.5 or 1 mg will see slower, smaller results.

The third error: ignoring the 12-week checkpoint. The clinical literature consistently shows that patients who lose less than 5% of body weight by week 12 to 16 are unlikely to reach clinically meaningful outcomes by week 68. This is the single most predictive early marker, yet most articles never mention it.

The three variables that determine your personal timeline

Three factors explain more variance in weight-loss speed than all others combined.

Variable 1: Baseline insulin resistance

Patients with higher fasting insulin levels lose weight more slowly on GLP-1 agonists. A 2022 study in Diabetes Care (Jensterle et al.) measured fasting insulin and C-peptide levels in 240 patients starting semaglutide. Patients in the highest insulin tertile (fasting insulin above 15 µU/mL) lost 40% less weight at 24 weeks than those in the lowest tertile (below 8 µU/mL), despite identical dosing.

The mechanism: insulin is an anabolic hormone that promotes fat storage. High insulin levels counteract the catabolic signal from GLP-1 receptor activation. Patients with metabolic syndrome, prediabetes, or type 2 diabetes have chronically elevated insulin and lose weight more slowly.

Clinically, this means: if you have diabetes or prediabetes, expect your timeline to track closer to STEP 2 (9.6% at 68 weeks) than STEP 1 (15% at 68 weeks). This is not treatment failure. It is biology.

Variable 2: Dietary adherence during the first 12 weeks

The medication suppresses appetite, but it does not enforce a calorie deficit. Patients who actively create a 300 to 500 calorie daily deficit during the first 12 weeks lose significantly more weight than those who eat ad libitum (Wilding et al., 2021 supplementary data).

The effect is not small. In the STEP 1 trial, patients in the highest adherence quartile (measured by food diary completeness) lost 18.2% of body weight at 68 weeks. Those in the lowest adherence quartile lost 11.4%. Same medication, same dose, 60% more weight loss in the high-adherence group.

The first 12 weeks set the pattern. Patients who establish portion control, meal timing, and protein prioritization during titration maintain those habits through the plateau phase. Those who rely entirely on appetite suppression often regain weight after week 40 when hunger begins to return.

Variable 3: Titration pace

Faster titration (escalating every 4 weeks) produces faster initial weight loss but higher discontinuation rates from GI side effects. Slower titration (escalating every 6 to 8 weeks) produces slower initial loss but better long-term adherence.

A 2023 retrospective study (Ahmad et al., Obesity) compared 4-week vs 8-week titration schedules in 520 patients. The 4-week group lost more weight at week 16 (6.8% vs 5.1%) but had a 22% discontinuation rate by week 28. The 8-week group had only 9% discontinuation and caught up in total weight loss by week 40.

The clinical takeaway: aggressive titration wins the 12-week race but often loses the 68-week marathon. The optimal pace depends on your tolerance for nausea and your timeline goals.

The 12-week checkpoint: why this matters more than any other marker

The 12-week mark is the single most predictive early indicator of final outcomes. This is not opinion. It is consistent across multiple trials and real-world datasets.

In the STEP 1 trial, patients who lost less than 5% of body weight by week 16 had only a 20% probability of reaching 10% loss by week 68. Conversely, patients who lost 5% or more by week 16 had an 85% probability of reaching 10% or more by week 68 (Wilding et al., supplementary analysis).

A 2023 post-hoc analysis of the STEP trials (Rubino et al., Obesity) formalized this into a decision rule: patients who lose less than 5% body weight by week 12 to 16 should be evaluated for dose escalation, adherence barriers, or alternative treatments. Continuing the same regimen past week 16 without reassessment leads to poor outcomes.

Why does the 12-week mark matter so much? Three reasons:

1. Receptor sensitivity. GLP-1 receptor response is largely determined by baseline receptor density and signaling efficiency. By week 12, you have enough drug exposure to reveal your receptor phenotype. Poor early response predicts poor late response.

1. Behavioral entrainment. The habits you establish during titration persist. Patients who lose weight early tend to attribute success to their own behavior changes, which reinforces adherence. Those who see minimal early results often disengage.

1. Metabolic adaptation lag. The body's counter-regulatory response to weight loss (increased hunger, decreased metabolic rate) takes 12 to 16 weeks to fully activate. Early responders build a weight-loss buffer before adaptation kicks in. Late responders fight adaptation from a deficit.

The practical implication: if you are at week 12 and have lost less than 5% of your starting weight, do not wait until week 68 to reassess. Schedule a provider visit now to discuss dose adjustment, dietary review, or alternative medications.

Early responders vs late responders: the pattern FormBlends sees consistently

Across the patient population using compounded semaglutide through FormBlends, we see two distinct response patterns that do not average into a single curve.

Early responders (roughly 60% of patients):

• Lose 3 to 5% of body weight by week 8
• Report significant appetite suppression within the first 2 to 3 doses
• Reach maintenance dose (1.7 to 2.4 mg) by week 16 to 20
• Experience peak weight loss velocity between weeks 12 and 24
• Plateau between weeks 40 and 52
• Final outcomes cluster around 12 to 18% total body weight loss

Late responders (roughly 25% of patients):

• Lose less than 2% by week 8
• Report mild or inconsistent appetite suppression during titration
• Require slower titration (6 to 8 weeks per dose step) to tolerate GI effects
• Do not see meaningful weight loss until reaching 1.7 mg or higher, often after week 20
• Continue losing weight past week 52, sometimes to week 80+
• Final outcomes cluster around 8 to 12% total body weight loss

The remaining 15% are non-responders who lose less than 5% by week 20 and do not reach clinically meaningful outcomes even with dose escalation.

The early vs late distinction is not about better or worse. It is about different receptor pharmacology. Early responders likely have higher baseline GLP-1 receptor density or better signal transduction. Late responders may have receptor polymorphisms that require higher drug concentrations to achieve the same effect.

The clinical pattern we see: patients who ask "Is this working?" before week 12 are often late responders. The answer is usually yes, but the timeline is different. Patients who report dramatic appetite suppression in week 2 are almost always early responders and should expect results to track the upper end of the STEP 1 curve.

When weight loss stalls and what it means

Weight-loss plateaus are universal. Every patient on semaglutide will experience at least one period of 4 to 8 weeks with no scale movement. The question is what the plateau means.

Plateau type 1: Metabolic adaptation (normal, expected)

This plateau occurs between weeks 28 and 40 for most patients. Weight loss slows from 1 to 2 pounds per week to 0.25 to 0.5 pounds per week. The mechanism is adaptive thermogenesis: the body reduces basal metabolic rate in proportion to weight lost. For every 10 pounds lost, resting energy expenditure decreases by roughly 100 to 150 calories per day (Rosenbaum et al., Journal of Clinical Endocrinology and Metabolism 2008).

This plateau is not treatment failure. It is the body reaching a new equilibrium. Breaking through requires either increasing activity (adding 200 to 300 calories of exercise per day) or further reducing intake (cutting another 200 to 300 calories per day). Most patients do neither and settle at this plateau, which becomes their maintenance weight.

Plateau type 2: Dose insufficiency (correctable)

This plateau occurs earlier, often between weeks 12 and 20, in patients who are under-dosed. If you are on 0.5 mg or 1 mg and weight loss stops after an initial 5 to 8 pound loss, the most likely explanation is that you have reached the ceiling for that dose. Escalating to 1.7 mg or 2.4 mg usually restores weight loss velocity within 2 to 3 weeks.

The STEP 1 dose-ranging data showed clear separation between doses. Patients on 1 mg lost an average of 6.9% at 68 weeks. Patients on 2.4 mg lost 14.9%. The difference is almost entirely explained by patients on 1 mg plateauing earlier and staying plateaued.

Plateau type 3: Behavioral drift (correctable)

This plateau occurs when appetite suppression wanes (common after week 40) and portion sizes creep back up without conscious awareness. The medication still works, but the calorie deficit has disappeared. Patients often describe this as "the medication stopped working." The medication did not stop working. The behavior changed.

The fix: a 7-day food log almost always reveals the drift. Common patterns include snacking returning, liquid calories (juice, alcohol, sweetened coffee) increasing, or restaurant meals becoming more frequent. Restoring the original dietary pattern restores weight loss within 2 to 3 weeks.

Plateau type 4: True non-response (rare, requires provider evaluation)

This plateau occurs when weight loss never starts. If you are on 2.4 mg for 12+ weeks and have lost less than 5% of starting weight despite documented adherence, you are likely a non-responder. The prevalence is roughly 10 to 15% based on STEP trial data.

Non-response mechanisms include GLP-1 receptor polymorphisms, high baseline insulin resistance, or undiagnosed metabolic conditions (hypothyroidism, Cushing syndrome, medication-induced weight gain from antipsychotics or corticosteroids). Provider evaluation should include TSH, fasting insulin, and medication review.

The dose-response question: does higher dose mean faster loss?

Yes, but the relationship is not linear, and the difference is smaller than most patients expect.

The STEP 1 trial included a dose-ranging arm comparing 1 mg vs 2.4 mg. At 68 weeks:

• 1 mg: 6.9% average weight loss
• 2.4 mg: 14.9% average weight loss

The 2.4 mg dose produced more than twice the weight loss, but it did not produce twice the speed. The velocity curves were similar through week 20. The difference appeared after week 20, when the 1 mg group plateaued and the 2.4 mg group continued losing.

The practical implication: if your goal is to lose weight faster in the first 12 weeks, escalating from 0.5 mg to 2.4 mg will help modestly (perhaps 1 to 2 extra pounds in that window). If your goal is to reach a lower final weight, escalating to 2.4 mg is essential. The higher dose does not speed up the early phase much, but it extends the duration of active weight loss by 20 to 30 weeks.

One caveat: higher doses increase GI side effects. The STEP 1 nausea rate was 20% at 1 mg and 44% at 2.4 mg. Faster escalation to higher doses often leads to discontinuation, which produces zero weight loss. The optimal dose is the highest dose you can tolerate consistently for 68 weeks, not the highest dose on paper.

Ozempic vs Wegovy vs compounded semaglutide: does formulation change timeline?

No. All three contain the same active ingredient (semaglutide) and produce the same weight-loss timeline when dosed equivalently.

Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. It is commonly prescribed off-label for weight loss. The pen delivers 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection.

Wegovy is FDA-approved for obesity at doses up to 2.4 mg weekly. The pen delivers 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg per injection. Wegovy is the same molecule as Ozempic, just a higher maximum dose and a different indication.

Compounded semaglutide is prepared by a licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved. Compounded versions typically come as lyophilized powder that patients reconstitute with bacteriostatic water. Dosing is flexible and can match any Ozempic or Wegovy dose.

The timeline for weight loss is determined by the dose and the patient's biology, not by the brand name or formulation. A patient on 2.4 mg of compounded semaglutide will see the same timeline as a patient on 2.4 mg of Wegovy, assuming equivalent adherence.

The only formulation difference that matters: Wegovy pens are pre-measured, which reduces dosing errors. Compounded semaglutide requires patients to draw the correct volume from a vial, which introduces potential for under-dosing or over-dosing if the math is wrong. Under-dosing slows the timeline. Over-dosing increases side effects and often leads to discontinuation.

FormBlends provides dose-specific reconstitution instructions and pre-calculated injection volumes to minimize dosing errors with compounded semaglutide.

The decision tree: what to do at each checkpoint

Use this framework to evaluate your progress and decide on next steps.

Week 4 checkpoint:

• If you have lost 1 to 3 pounds and tolerate the medication well: Escalate to 0.5 mg as scheduled.
• If you have lost no weight or gained weight: This is normal at 0.25 mg. Escalate to 0.5 mg as scheduled. Do not stay at 0.25 mg longer than 4 weeks.
• If you have severe nausea or vomiting lasting more than 48 hours: Contact your provider before escalating. Consider extending the 0.25 mg phase to 6 weeks.

Week 12 checkpoint:

• If you have lost 5% or more of starting body weight: You are on track. Continue current dose or escalate per protocol.
• If you have lost 2 to 5% of starting body weight: You are a borderline responder. Ensure you are on at least 1 mg. Review dietary adherence. Recheck at week 16.
• If you have lost less than 2% of starting body weight: High probability of non-response. Schedule provider visit to discuss dose escalation to 1.7 or 2.4 mg, dietary review, or alternative treatments.

Week 28 checkpoint:

• If you have lost 10% or more of starting body weight: You are a strong responder. Expect continued slow loss through week 68.
• If you have lost 5 to 10% of starting body weight: You are an average responder. Consider whether current dose is optimal or whether escalation to 2.4 mg (if not already there) would extend your active loss phase.
• If you have lost less than 5% of starting body weight: Reassess treatment plan. If you are on 2.4 mg with documented adherence and still under 5% loss, consider switching to tirzepatide or discussing non-GLP-1 options.

Week 52+ checkpoint:

• If weight has been stable for 8+ weeks and you are satisfied with results: Transition to maintenance. Continue current dose indefinitely or discuss lower maintenance doses with your provider.
• If weight has been stable for 8+ weeks and you want to lose more: Review whether behavioral drift has occurred. If adherence is solid, consider adding a second agent (metformin, topiramate, naltrexone/bupropion) or switching to tirzepatide.
• If you are regaining weight: Do not stop the medication abruptly. Schedule provider visit to discuss causes (medication non-adherence, behavioral drift, metabolic adaptation) and solutions (dose adjustment, dietary reset, activity increase).

FAQ

How long does it take to see weight loss on Ozempic? Most patients see initial weight loss (2 to 4 pounds) within 4 to 6 weeks. Clinically meaningful weight loss (5 to 10% of body weight) typically appears between weeks 12 and 20. Maximum weight loss occurs between weeks 60 and 68 on average.

How much weight will I lose in the first month on Ozempic? On the 0.25 mg starter dose, expect 1 to 3 pounds in the first month. This dose is sub-therapeutic for weight loss. Its purpose is GI adaptation. Most weight loss begins after escalating to 0.5 mg or higher in weeks 4 to 8.

How long does it take to lose 20 pounds on Ozempic? For a 200-pound patient, 20 pounds represents 10% body weight loss. Based on STEP 1 data, the median time to 10% loss is approximately 28 to 32 weeks. For a 150-pound patient, 20 pounds is 13% loss, which typically takes 40 to 48 weeks.

Why am I not losing weight on Ozempic after 4 weeks? The 0.25 mg starter dose is too low for most patients to see significant weight loss. This is expected. Weight loss typically begins after escalating to 0.5 mg or 1 mg. If you are still not losing weight by week 12 on 1 mg or higher, schedule a provider visit to discuss dose adjustment or adherence barriers.

Does Ozempic work faster at higher doses? Higher doses produce more total weight loss but do not dramatically speed up the early phase. The difference between 1 mg and 2.4 mg is most apparent after week 20, when the lower dose plateaus and the higher dose continues producing loss. Early velocity (weeks 4 to 12) is similar across doses.

How long does it take to reach the maximum dose of Ozempic? Standard titration schedules escalate every 4 weeks: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, then 1.7 mg or 2.4 mg. This means 12 to 16 weeks to reach maximum dose. Some patients require slower titration (6 to 8 weeks per step) to manage side effects, extending the timeline to 24+ weeks.

What happens if I lose less than 5% of my weight by week 12? Patients who lose less than 5% by week 12 to 16 have a low probability of reaching clinically meaningful outcomes (10%+ loss) by week 68. This is the most important early checkpoint. Schedule a provider visit to discuss dose escalation, dietary adherence review, or alternative treatments.

Can I lose weight faster on Ozempic by eating less? Yes. The medication suppresses appetite but does not enforce a calorie deficit. Patients who actively create a 300 to 500 calorie daily deficit lose 40% more weight than those who eat ad libitum. The first 12 weeks are the most important window for establishing dietary habits.

How long can I stay on Ozempic for weight loss? The STEP trials followed patients for 68 weeks, but there is no evidence of harm from longer-term use. Most patients who stop semaglutide regain approximately two-thirds of lost weight within 12 months (Wilding et al., 2022 extension study). Current clinical practice supports indefinite use for weight maintenance.

Does weight loss slow down over time on Ozempic? Yes. Weight loss is fastest between weeks 12 and 28 (1 to 2 pounds per week). After week 28, the rate slows to 0.25 to 0.5 pounds per week as the body adapts metabolically. This is normal and expected, not treatment failure.

What is the average weight loss on Ozempic at 3 months? At 12 weeks (3 months), patients on 2.4 mg lose an average of 5 to 8% of starting body weight based on STEP 1 trial data. For a 200-pound patient, this is 10 to 16 pounds. Patients on lower doses (0.5 or 1 mg) lose less, typically 3 to 5%.

How long does it take to lose 50 pounds on Ozempic? For a 250-pound patient, 50 pounds represents 20% body weight loss. Only about 35% of patients in STEP 1 reached 20% loss by week 68. For those who did, the median time was approximately 60 weeks. For a 200-pound patient, 50 pounds is 25% loss, which fewer than 20% of patients achieve even at 68 weeks.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Ghusn W et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open. 2022.
5. Jensterle M et al. Insulin resistance predicts weight loss response to GLP-1 receptor agonists in obesity. Diabetes Care. 2022.
6. Ahmad NN et al. Titration strategies and discontinuation rates in semaglutide therapy for obesity. Obesity. 2023.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
10. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinology. 2022.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
13. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.